Palvella Therapeutics (PVLA) Competitors

Ardelyx (NASDAQ:ARDX) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, community ranking, analyst recommendations, profitability and valuation.

Do insiders & institutionals have more ownership in ARDX or PVLA?

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are held by institutional investors. 5.9% of Ardelyx shares are held by company insiders. Comparatively, 6.4% of Palvella Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has better earnings & valuation, ARDX or PVLA?

Palvella Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Palvella Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$333.62M	3.89	-$39.14M	-$0.16	-34.06
Palvella Therapeutics	$42.81M	6.03	-$24.54M	-$12.10	-1.94

Does the MarketBeat Community favor ARDX or PVLA?

Ardelyx received 524 more outperform votes than Palvella Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Palvella Therapeutics an outperform vote while only 67.46% of users gave Ardelyx an outperform vote.

Company	Underperform	Outperform
Ardelyx	Outperform Votes 537 67.46%	Underperform Votes 259 32.54%
Palvella Therapeutics	Outperform Votes 13 100.00%	Underperform Votes No Votes

Does the media refer more to ARDX or PVLA?

In the previous week, Ardelyx had 3 more articles in the media than Palvella Therapeutics. MarketBeat recorded 10 mentions for Ardelyx and 7 mentions for Palvella Therapeutics. Ardelyx's average media sentiment score of 1.35 beat Palvella Therapeutics' score of 0.78 indicating that Ardelyx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ARDX or PVLA more profitable?

Palvella Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -11.73%. Ardelyx's return on equity of -24.87% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-11.73%	-24.87%	-10.51%
Palvella Therapeutics	N/A	-80.93%	-59.55%

Do analysts prefer ARDX or PVLA?

Ardelyx presently has a consensus price target of $10.61, suggesting a potential upside of 94.70%. Palvella Therapeutics has a consensus price target of $44.43, suggesting a potential upside of 89.54%. Given Ardelyx's higher probable upside, equities analysts clearly believe Ardelyx is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Palvella Therapeutics	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13

Which has more volatility & risk, ARDX or PVLA?

Ardelyx has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Comparatively, Palvella Therapeutics has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500.

Summary

Ardelyx beats Palvella Therapeutics on 11 of the 19 factors compared between the two stocks.